A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase III Study to Evaluate the Efficacy and Safety of PBK_L2201 in Postmenopausal Women With Osteoporosis
Latest Information Update: 07 Dec 2023
At a glance
- Drugs Abaloparatide (Primary)
- Indications Postmenopausal osteoporosis
- Focus Therapeutic Use
- Sponsors Pharmbio Korea
- 07 Dec 2023 New trial record